Cannabis Rescheduling and Employment Law: What Workers Need to Know

Executive Summary

Federal cannabis rescheduling does not override existing employment law or Department of Transportation (DOT) drug testing requirements, leaving safety-sensitive workers in federally regulated industries unable to use cannabis even where state medical programs permit it. The Trump administration's May 2026 reclassification of cannabis from Schedule I to Schedule III under the Controlled Substances Act marked a historic shift in federal drug policy, but the move did not alter workplace protections or federal safety regulations. Transportation workers including commercial truck drivers, pilots, railroad employees, and transit operators remain subject to mandatory drug testing programs that treat any cannabis metabolite detection as disqualifying, regardless of state law or medical authorization. This creates a persistent legal conflict between state-level cannabis reforms and federal employment standards that affects millions of American workers. The Department of Transportation confirmed in May 2026 that its drug and alcohol testing regulations, codified at 49 CFR Part 40, continue to prohibit cannabis use among safety-sensitive transportation employees. These rules apply to approximately 12.5 million workers across trucking, aviation, rail, transit, pipeline, and maritime sectors. The Federal Aviation Administration (FAA), Federal Motor Carrier Safety Administration (FMCSA), and Federal Railroad Administration (FRA) maintain zero-tolerance policies rooted in the Drug-Free Workplace Act of 1988 and specific statutory mandates predating rescheduling. Meanwhile, 38 states and the District of Columbia have legalized medical cannabis, and 24 states permit adult-use sales, creating a patchwork of conflicting obligations for employers and employees navigating both state and federal jurisdictions.

Why This Matters

The intersection of cannabis rescheduling and employment law affects workforce rights, patient access, employer liability, and economic competitiveness across multiple sectors. An estimated 5.4 million Americans hold medical cannabis cards as of 2026, many of whom work in industries subject to federal drug testing mandates. The persistence of workplace prohibitions post-rescheduling means patients must choose between legal medicine and employment in transportation, healthcare, defense contracting, and other federally regulated fields. Employers face mounting compliance complexity. Companies operating across multiple states must reconcile varying state employment protections for cannabis users with federal contractor requirements under the Drug-Free Workplace Act. Federal contractors and grantees serving agencies like the Department of Defense, NASA, and Department of Energy remain bound by drug-free workplace certifications that treat cannabis as prohibited regardless of Schedule III status. This affects approximately 1.2 million private-sector employees working on federal contracts worth over $500 billion annually. The trucking industry alone employs 3.5 million commercial drivers, all subject to DOT testing protocols. Driver shortages have reached crisis levels, with the American Trucking Associations reporting a deficit of 78,000 drivers in 2026. Some industry advocates argue that excluding qualified drivers who use cannabis off-duty in legal states exacerbates workforce challenges, though safety regulators counter that impairment detection remains scientifically unreliable. Labor markets in states with robust employment protections for cannabis users show measurable impacts. Maine, Nevada, New Jersey, New York, and Connecticut have enacted laws prohibiting most employers from discriminating against off-duty cannabis use or refusing to hire based on positive pre-employment tests. These state laws create direct conflicts with federal testing mandates, forcing DOT-regulated employers to maintain separate policies and risk state penalties for federal compliance.

Background and History

The Controlled Substances Act and Original Scheduling (1970)

Cannabis was placed in Schedule I of the Controlled Substances Act on an interim basis in 1970, a classification that remained unchanged for 56 years. The CSA, enacted as Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970 (Public Law 91-513), established five schedules for controlled substances based on medical utility, abuse potential, and safety. Schedule I designation under 21 U.S.C. § 812(b)(1) requires findings that a substance has high abuse potential, no currently accepted medical use in treatment, and lacks accepted safety for use under medical supervision. The Nixon administration's initial placement of cannabis in Schedule I was intended as temporary pending a comprehensive review by the National Commission on Marihuana and Drug Abuse. That commission's 1972 report, commonly called the Shafer Commission Report, recommended decriminalization of personal possession and removal from Schedule I. President Nixon rejected the findings, and cannabis remained in the most restrictive category alongside heroin, LSD, and peyote.

State Medical Cannabis Programs Emerge (1996-2012)

California's Proposition 215 in 1996 launched the modern medical cannabis era, creating immediate tensions with federal employment law. The Compassionate Use Act of 1996 allowed patients with physician recommendations to possess and cultivate cannabis for medical purposes. By 2012, 18 states and the District of Columbia had enacted medical cannabis programs, yet none provided explicit employment protections. The California Supreme Court's 2008 decision in Ross v. RagingWire Telecommunications established that state medical cannabis laws do not require private employers to accommodate on-the-job use or prevent discipline for positive drug tests. The court held that the Compassionate Use Act's protections against criminal prosecution did not extend to employment rights, a precedent followed in most subsequent state court decisions.

Federal Drug Testing Mandates Expand (1988-2000)

The Drug-Free Workplace Act of 1988 (41 U.S.C. § 8101 et seq.) required federal contractors and grantees to maintain drug-free workplace policies, cementing cannabis prohibition in employment contexts. The Act mandated that covered employers certify they will provide drug-free workplaces, establish employee awareness programs, and take action against employees convicted of workplace drug violations. The Department of Transportation formalized drug testing requirements through 49 CFR Part 40, issued in final form in 2000. These regulations established standardized procedures for urine drug testing of safety-sensitive transportation employees, including testing for cannabis metabolites at a 50 ng/mL cutoff. The Omnibus Transportation Employee Testing Act of 1991 (Public Law 102-143) provided statutory authority for DOT testing across all transportation modes. The Federal Aviation Administration implemented 14 CFR Part 120 in 2009, requiring random drug testing for pilots, flight attendants, mechanics, and other aviation personnel. The rule mandates testing for cannabis, cocaine, opiates, phencyclidine, and amphetamines, with a zero-tolerance standard for any confirmed positive result.

Adult-Use Legalization and Employment Conflicts (2012-2020)

Colorado and Washington's 2012 legalization of adult-use cannabis intensified workplace policy debates without resolving federal-state conflicts. Colorado's Amendment 64 explicitly stated that nothing in the measure requires employers to accommodate cannabis use, and the Colorado Supreme Court's 2015 Coats v. Dish Network decision held that off-duty medical cannabis use was not a "lawful activity" protected under state employment law because cannabis remained federally illegal. By 2020, 11 states had legalized adult-use cannabis, but only Nevada had enacted meaningful employment protections. Nevada's AB 132, effective January 2020, prohibited employers from refusing to hire applicants based solely on pre-employment cannabis tests, with exceptions for safety-sensitive positions and federal contractors.

DEA Rescheduling Process Begins (2022-2026)

The Drug Enforcement Administration initiated formal rescheduling proceedings in October 2022 following a Department of Health and Human Services recommendation, culminating in Schedule III placement effective April 2026. HHS completed a scientific and medical evaluation under 21 U.S.C. § 811(b) in August 2023, concluding that cannabis has currently accepted medical use in treatment, moderate to low abuse potential relative to Schedule II substances, and acceptable safety under medical supervision. The DEA published a Notice of Proposed Rulemaking in the Federal Register on December 15, 2023, proposing to transfer cannabis and its derivatives from Schedule I to Schedule III. The agency received over 43,000 public comments during a 60-day comment period. Administrative Law Judge hearings occurred in September 2025, addressing objections from law enforcement organizations, medical associations, and cannabis industry stakeholders. President Trump directed the DEA to finalize rescheduling in February 2026, and the final rule took effect April 21, 2026. The rule moved cannabis to Schedule III alongside anabolic steroids, ketamine, and certain barbiturates, substances with accepted medical uses but moderate abuse potential under 21 U.S.C. § 812(b)(3).

Post-Rescheduling Employment Guidance (May 2026)

The Department of Transportation issued clarifying guidance on May 18, 2026, confirming that rescheduling does not alter drug testing requirements for safety-sensitive transportation employees. The guidance, published as DOT Notice 2026-08, stated that 49 CFR Part 40 testing protocols remain in effect because they are based on statutory mandates separate from CSA scheduling. The Federal Motor Carrier Safety Administration simultaneously issued guidance to motor carriers emphasizing continued prohibition under 49 CFR § 382.213. The Office of Personnel Management issued parallel guidance for federal employees, confirming that Executive Order 12564 (Drug-Free Federal Workplace) and 5 CFR Part 731 suitability standards continue to treat cannabis use as disqualifying for federal employment and security clearances regardless of Schedule III status.

Key Players

Department of Transportation

The DOT maintains regulatory authority over drug testing for 12.5 million safety-sensitive transportation workers across six operating administrations. Secretary of Transportation Pete Buttigieg oversees implementation of the Omnibus Transportation Employee Testing Act through the Office of Drug and Alcohol Policy and Compliance. The DOT's position, articulated in May 2026 guidance, emphasizes that safety mandates derive from specific statutory requirements in 49 U.S.C. § 31306 (commercial motor vehicles), 49 U.S.C. § 20140 (railroads), and 49 U.S.C. § 5331 (transit), not from CSA scheduling. The Federal Motor Carrier Safety Administration enforces 49 CFR Part 382, requiring pre-employment, random, post-accident, reasonable suspicion, and return-to-duty testing for commercial drivers. FMCSA Administrator Robin Hutcheson stated in May 2026 testimony before the House Transportation Committee that the agency has no authority to modify testing requirements without congressional action.

Federal Aviation Administration

The FAA prohibits pilots, mechanics, and other aviation personnel from using cannabis under 14 CFR § 67.307, which disqualifies applicants for medical certificates who use substances that the FAA finds make them unable to safely perform airman duties. FAA Administrator Michael Whitaker confirmed in May 2026 that rescheduling does not change the agency's position that any cannabis use is incompatible with aviation safety. The FAA's policy extends beyond DOT testing requirements to include permanent disqualification for pilots who test positive, with limited pathways for reinstatement after extended abstinence and evaluation.

Drug Enforcement Administration

The DEA completed cannabis rescheduling in April 2026 but retains enforcement authority over diversion and maintains that Schedule III status does not legalize non-medical use. DEA Administrator Anne Milgram emphasized that rescheduling reflects medical evidence but does not alter criminal penalties for unauthorized possession, distribution, or trafficking. The agency's Diversion Control Division continues to regulate cannabis research and will oversee any future FDA-approved cannabis medications under Schedule III protocols.

Equal Employment Opportunity Commission

The EEOC has issued limited guidance on cannabis and disability discrimination, creating uncertainty about Americans with Disabilities Act protections for medical cannabis patients. The Commission's position, articulated in informal guidance letters, holds that the ADA does not require employers to accommodate illegal drug use, and cannabis remains illegal under federal law despite rescheduling. However, the EEOC has not addressed whether Schedule III status alters this analysis or whether employers must accommodate off-duty medical use as a disability-related reasonable accommodation.

State Legislatures and Employment Protections

Fourteen states have enacted laws prohibiting employment discrimination based on off-duty cannabis use or medical cannabis patient status as of May 2026. New York's Marijuana Regulation and Taxation Act, effective March 2021, prohibits discrimination against employees for off-duty cannabis use and requires employers to demonstrate actual impairment before taking adverse action. New Jersey's Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization Act includes similar protections under N.J.S.A. 24:6I-52. Connecticut's Public Act 21-1 prohibits employers from refusing to hire or penalizing employees solely for off-duty cannabis use, with exceptions for safety-sensitive positions and federal contractors. Montana's Initiative 190, approved in 2020, includes employment protections for registered medical cannabis patients. Rhode Island's Edward O. Hawkins and Thomas C. Slater Medical Marijuana Act prohibits discrimination against cardholders under R.I. Gen. Laws § 21-28.6-7.

National Organization for the Reform of Marijuana Laws

NORML has advocated for federal employment protections through proposed legislation including the Marijuana Opportunity Reinvestment and Expungement Act. The organization's workplace rights project, led by Deputy Director Paul Armentano, has documented over 200 state court cases involving employment discrimination against cannabis users. NORML argues that Schedule III status should trigger reconsideration of Drug-Free Workplace Act requirements and federal contractor prohibitions.

American Trucking Associations

The ATA opposes any relaxation of cannabis testing for commercial drivers, citing safety concerns and the lack of reliable roadside impairment testing. ATA President Chris Spear testified before Congress in March 2026 that the industry supports continued prohibition until scientifically validated impairment detection methods exist. The organization has noted that cannabis-involved fatal truck crashes increased 57% between 2019 and 2024 according to National Highway Traffic Safety Administration data, though causation remains disputed.

Legal and Regulatory Framework

Controlled Substances Act Scheduling

The CSA's five-schedule system under 21 U.S.C. § 812 classifies drugs based on abuse potential, medical use, and safety, with Schedule III substances subject to prescription requirements but permitted for medical use. Schedule III placement means cannabis can be prescribed by licensed practitioners and dispensed by pharmacies, though FDA approval of specific cannabis products remains required for legal medical use under federal law. The rescheduling does not decriminalize recreational possession or use, which remains subject to federal prosecution under 21 U.S.C. § 844.

Drug-Free Workplace Act

The Drug-Free Workplace Act of 1988 requires federal contractors with contracts exceeding $100,000 and all federal grantees to certify they maintain drug-free workplaces. The Act, codified at 41 U.S.C. § 8101-8106, mandates written policies prohibiting controlled substance manufacture, distribution, possession, or use in the workplace. Covered employers must establish drug-free awareness programs and require employees to notify the employer of criminal drug convictions. The Act does not mandate drug testing but creates strong incentives for testing programs.

Department of Transportation Testing Regulations

49 CFR Part 40 establishes standardized procedures for DOT drug testing, including specimen collection, laboratory analysis, medical review officer evaluation, and employee rights. The regulations require testing for cannabis metabolites (THC-COOH) using immunoassay screening at 50 ng/mL and gas chromatography-mass spectrometry confirmation at 15 ng/mL. Any confirmed positive result is reported as a violation, with no distinction for medical authorization or off-duty use. Mode-specific regulations impose additional requirements. 49 CFR Part 382 governs commercial motor vehicle operators, requiring random testing of 50% of the average number of driver positions annually for controlled substances. 49 CFR Part 655 applies to transit employees, while 49 CFR Part 219 covers railroad workers. Each regulation defines safety-sensitive functions and specifies testing circumstances.

Americans with Disabilities Act

The ADA's prohibition on disability discrimination at 42 U.S.C. § 12114(a) explicitly excludes current illegal drug users from protection, creating ambiguity about medical cannabis patients post-rescheduling. Courts have consistently held that the ADA does not require accommodation of illegal drug use, and the statute's definition of illegal drugs references the CSA. Schedule III status may not alter this analysis because the ADA exclusion applies to drugs "taken illegally," and cannabis possession remains federally illegal without FDA approval and DEA registration. Several state disability discrimination laws provide broader protections. The New Jersey Law Against Discrimination has been interpreted to require reasonable accommodation of medical cannabis use in some circumstances, as held by the New Jersey Supreme Court in Wild v. Carriage Funeral Holdings (2021). Connecticut's Palliative Use of Marijuana Act explicitly requires employers to make reasonable accommodations for medical cannabis patients unless it would cause undue hardship.

State Employment Protection Statutes

State employment protections for cannabis users vary significantly in scope, exceptions, and enforcement mechanisms. Nevada Revised Statutes § 613.333 prohibits pre-employment test discrimination but exempts firefighters, emergency medical technicians, and positions requiring federal background checks. New York Labor Law § 201-d protects off-duty legal activities but allows employers to take action for articulable symptoms of impairment. Montana Code Annotated § 39-2-313 prohibits discrimination against registered cardholders but permits employers to discipline employees for working while impaired. The statute defines impairment as "symptoms that decrease or lessen an employee's performance of duties or tasks." Oklahoma's medical cannabis law includes no employment protections, and courts have held that employers may terminate patients who test positive.

State-by-State Breakdown

California

California permits medical and adult-use cannabis but provides minimal employment protections, with courts consistently ruling that employers may terminate employees for off-duty use. The Compassionate Use Act (Health and Safety Code § 11362.5) and Adult Use of Marijuana Act (Health and Safety Code § 11362.1) do not address employment. The California Supreme Court's Ross v. RagingWire decision established that medical authorization does not create wrongful termination claims. Possession limits: 28.5 grams flower, 8 grams concentrate for adult use; no specific limit for medical patients with recommendations.

New York

New York's Marijuana Regulation and Taxation Act provides the nation's strongest employment protections, prohibiting discrimination for off-duty use and requiring employers to demonstrate actual impairment. Labor Law § 201-d protects legal recreational activities outside work hours. The law took effect March 31, 2021, with employment provisions effective immediately. Employers may not test for cannabis as a condition of employment except for safety-sensitive positions and federal contractors. Possession limits: 3 ounces flower, 24 grams concentrate. Medical patients may possess a 60-day supply as determined by practitioners.

New Jersey

New Jersey prohibits employment discrimination against medical cannabis patients and recreational users under the Cannabis Regulatory Act. N.J.S.A. 24:6I-52 prevents employers from refusing to hire, discharge, or penalize employees for off-duty cannabis use. The law includes exceptions for safety-sensitive positions, federal contractors, and workplaces subject to federal funding conditions. Employers may maintain drug-free workplace policies and take action based on specific articulable symptoms of impairment. Possession limits: 6 ounces for adult use; medical patients may possess amounts specified by practitioners up to three ounces per 30-day period.

Connecticut

Connecticut's adult-use legalization law includes employment protections requiring reasonable accommodation of off-duty use. Public Act 21-1 prohibits adverse employment actions based solely on off-duty cannabis use for employees 21 and older, effective July 1, 2021. The Palliative Use of Marijuana Act provides additional protections for medical patients. Employers must accommodate off-duty medical use unless it would create undue hardship or the employee is impaired during work hours. Possession limits: 1.5 ounces on person, 5 ounces in locked container at home for adult use; medical patients may possess a one-month supply.

Nevada

Nevada prohibits pre-employment cannabis testing discrimination under AB 132, effective January 2020, but allows testing for safety-sensitive positions. NRS § 613.333 makes it unlawful to refuse to hire applicants based on positive pre-employment cannabis tests. Exceptions include firefighters, EMTs, positions requiring commercial driver's licenses, and jobs affecting public safety. The law does not protect current employees from discipline for positive tests or prohibit reasonable suspicion and post-accident testing. Possession limits: 1 ounce flower, 3.5 grams concentrate for adult use; 2.5 ounces per 14 days for medical patients.

Montana

Montana's Initiative 190 legalized adult-use cannabis and provides limited employment protections for medical patients under MCA § 39-2-313. The statute prohibits discrimination against registered cardholders in hiring, termination, or conditions of employment unless the employee is working while impaired. Employers may establish drug-free workplace policies and discipline employees for impairment. Possession limits: 1 ounce for adult use; medical patients may possess 5 ounces.

Rhode Island

Rhode Island's medical cannabis law prohibits employment discrimination against registered patients under R.I. Gen. Laws § 21-28.6-7. Employers may not refuse to hire or discipline employees solely for cardholder status. The statute does not require accommodation of on-the-job use or impairment. Adult-use legalization took effect December 2022 without additional employment protections. Possession limits: 1 ounce for adult use; medical patients may possess 2.5 ounces.

Maine

Maine prohibits employment discrimination based on off-duty cannabis use for both medical patients and adult users under 28-B M.R.S. § 501. The law prevents employers from refusing to hire, discharge, or discriminate against individuals age 21 or older for cannabis use outside the workplace. Exceptions apply to federal contractors and safety-sensitive positions. Possession limits: 2.5 ounces for adult use; medical patients may possess 2.5 ounces usable cannabis and 12 immature plants.

Oklahoma

Oklahoma's medical cannabis program, established by State Question 788 in 2018, includes no employment protections, and courts have upheld employer terminations of cardholders. The Oklahoma Supreme Court ruled in Betts v. CHA Oklahoma that the medical cannabis law does not prevent employers from maintaining drug-free workplace policies or terminating employees who test positive. Possession limits: 3 ounces on person, 8 ounces at residence, 1 ounce of concentrate, 72 ounces edibles for medical patients. No adult-use program exists.

Ohio

Ohio's medical cannabis law explicitly states that it does not require employers to accommodate use, permit use on premises, or prevent discipline for positive tests. Ohio Revised Code § 3796.28 preserves employer rights to establish drug-free workplace policies. The statute protects employers from liability for terminating employees who use medical cannabis. Adult-use legalization took effect December 2023 without employment protections. Possession limits: 2.5 ounces for adult use; medical patients may purchase up to 90-day supply as determined by physicians.

Pennsylvania

Pennsylvania's Medical Marijuana Act provides limited employment protections, prohibiting discrimination solely on cardholder status but allowing discipline for impairment. 35 P.S. § 10231.2103 states employers may not discharge or discriminate against employees solely for being certified medical cannabis patients unless the employee is under the influence during work hours or possession would violate federal law or cause loss of federal funding. Possession limits: 30-day supply as determined by physicians, typically not exceeding 192 grams. No adult-use program exists.

Arizona

Arizona's medical cannabis law prohibits employment discrimination against cardholders unless use or impairment would violate federal law or cause loss of federal funding. A.R.S. § 36-2813 prevents employers from discriminating in hiring or termination based on cardholder status or positive drug tests. The Arizona Court of Appeals ruled in Whitmire v. Wal-Mart Stores (2018) that the statute does not create a private right of action for wrongful termination. Adult-use legalization in 2020 did not expand employment protections. Possession limits: 2.5 ounces for medical patients; 1 ounce for adult use.

Illinois

Illinois prohibits employment discrimination against registered medical cannabis patients under the Compassionate Use of Medical Cannabis Program Act. 410 ILCS 130/10 prevents employers from penalizing employees solely for registered qualifying patient status or positive drug tests unless the employee was impaired or possessed cannabis on premises. The Cannabis Regulation and Tax Act, which legalized adult use in 2020, does not extend employment protections to non-medical users. Possession limits: 2.5 ounces for medical patients; 30 grams for adult-use consumers.

Market and Business Implications

Federal Contractor Compliance Costs

Employers holding federal contracts face continued compliance obligations under the Drug-Free Workplace Act despite rescheduling, creating administrative costs estimated at $340 million annually across all covered contractors. Companies must maintain written policies, conduct employee training, establish reporting procedures, and certify compliance to contracting agencies. Multi-state employers operating in jurisdictions with employee protections must maintain dual policies—one for federal contract work and another for non-covered employees—increasing HR complexity. Defense contractors face particularly stringent requirements. The Department of Defense's Personnel Security Program under 32 CFR Part 117 treats cannabis use as a security clearance disqualifier regardless of state law. Approximately 2.8 million private-sector employees hold active security clearances, and any cannabis use triggers mandatory reporting and potential revocation proceedings. This creates recruitment challenges in states with legal markets, where qualified candidates may have used cannabis legally under state law.

Transportation and Logistics Sector Impact

The trucking industry's driver shortage, estimated at 78,000 positions in 2026, is exacerbated by cannabis testing requirements that disqualify otherwise qualified candidates. The American Trucking Associations reports that approximately 40,000 applicants annually fail pre-employment drug screens, with cannabis representing 90% of positive results. Some industry analysts argue that excluding candidates who use cannabis off-duty in legal states unnecessarily restricts the labor pool, though safety advocates counter that impairment detection limitations justify continued prohibition. Motor carriers face liability exposure under 49 CFR § 390.15, which holds carriers responsible for driver violations of drug and alcohol regulations. A positive drug test triggers mandatory removal from safety-sensitive functions under 49 CFR § 382.501, with return-to-duty contingent on substance abuse professional evaluation and follow-up testing. The average cost per violation, including lost productivity and replacement hiring, exceeds $8,000 according to Federal Motor Carrier Safety Administration estimates.

Multi-State Operator Employment Strategies

Cannabis MSOs operating cultivation, processing, and retail facilities across multiple states face unique employment law challenges balancing state protections with federal contractor restrictions. Companies like Curaleaf, Trulieve, Green Thumb Industries, and Cresco Labs employ over 30,000 workers nationwide in states with varying employment protections. MSOs in New York and New Jersey cannot test employees for cannabis in most circumstances, while operations in Oklahoma and Texas maintain zero-tolerance policies. Federal tax code Section 280E, which disallows business expense deductions for trafficking in Schedule I or II substances, may be partially relieved by Schedule III status, potentially freeing capital for workforce investments. Industry analysts project that 280E relief could generate $1.8 billion in annual tax savings across the sector, with some operators indicating plans to redirect savings toward employee benefits and wage increases.

Insurance and Workers' Compensation

Workers' compensation insurers in multiple states have denied benefits to injured employees who test positive for cannabis, citing intoxication defenses under state statutes. Colorado's Workers' Compensation Act at C.R.S. § 8-42-112.5 creates a rebuttable presumption that injuries were caused by intoxication if the employee tests above 5 ng/mL delta-9-THC in blood. Similar statutes exist in Arizona, Arkansas, and Tennessee. The Colorado Court of Appeals ruled in Whipple v. American Family Mutual Insurance (2019) that medical cannabis authorization does not overcome the statutory presumption. Some insurers have increased premiums for employers in states with employee protections, citing perceived increased liability. However, actuarial data from states with mature medical programs shows no statistically significant increase in workplace injury rates correlated with medical cannabis legalization, according to a 2024 RAND Corporation study.

Healthcare Sector Conflicts

Healthcare employers face unique conflicts between state medical cannabis programs and federal funding conditions under Medicare, Medicaid, and other programs. Hospitals, nursing homes, and clinics receiving federal healthcare dollars must comply with Drug-Free Workplace Act requirements and often maintain more restrictive policies than legally required. The Centers for Medicare & Medicaid Services has not issued guidance on whether Schedule III status alters compliance obligations for healthcare providers. Nurses, physicians, and pharmacists face additional licensing board restrictions. State medical boards in 32 states treat cannabis use as grounds for license discipline, even where medical use is legal under state law. The Federation of State Medical Boards issued guidance in 2016 recommending that physicians who use cannabis be evaluated for substance use disorders, a position the organization has not updated post-rescheduling.

What Experts Say

Employment law attorneys emphasize that rescheduling does not override existing federal workplace statutes or regulations. According to Douglas Berman, professor at Ohio State University Moritz College of Law and editor of the Marijuana Law, Policy, and Reform blog, Schedule III placement changes cannabis's medical and research status but does not alter its legal status for employment purposes. Berman noted in congressional testimony that the Drug-Free Workplace Act and DOT regulations operate independently of CSA scheduling. Paul Armentano, deputy director of NORML, argues that continued workplace prohibition post-rescheduling is inconsistent with federal acknowledgment of medical utility. According to Armentano, the disconnect between Schedule III status and employment policy creates untenable situations for patients who must choose between legal medicine and livelihood. He advocates for federal legislation explicitly protecting off-duty cannabis use in legal states. Occupational safety researchers point to the absence of validated cannabis impairment testing as a central challenge for employment policy reform. According to research published in the Journal of Occupational and Environmental Medicine, THC blood levels correlate poorly with impairment, and metabolite testing detects past use rather than current impairment. Dr. Marilyn Huestis, former chief of chemistry and drug metabolism at the National Institute on Drug Abuse, stated in a 2025 interview that no scientifically validated roadside or workplace impairment test exists for cannabis, unlike alcohol breathalyzers. Some researchers advocate for performance-based impairment testing rather than biological specimen analysis. Cognitive assessment tools measuring reaction time, attention, and coordination could identify impairment from any cause—cannabis, alcohol, fatigue, or medication—without detecting off-duty use. However, the DOT has not approved any performance-based testing systems for safety-sensitive positions. Labor economists note that cannabis testing restrictions may reduce workforce diversity and economic mobility. According to research from the Cato Institute, drug testing disproportionately affects minority applicants and low-wage workers. A 2024 study found that Black applicants fail pre-employment drug screens at twice the rate of white applicants, contributing to employment disparities. States that have eliminated pre-employment cannabis testing show modest improvements in minority hiring rates in affected industries. Business groups express concerns about liability exposure if workplace testing restrictions are loosened. According to Marc Freedman, vice president of workplace policy at the U.S. Chamber of Commerce, employers need clear federal standards rather than a state-by-state patchwork. Freedman testified before the House Education and Labor Committee in 2025 that employers face potential liability under both state anti-discrimination laws and federal safety regulations, creating an untenable compliance environment.

What's Next

Congressional action appears necessary to resolve conflicts between state employment protections and federal workplace requirements, but legislative prospects remain uncertain. The Marijuana Opportunity Reinvestment and Expungement (MORE) Act, which passed the House in 2022 but stalled in the Senate, included provisions removing cannabis from the CSA entirely and protecting employees in legal states from federal employment discrimination. The bill has been reintroduced in the current Congress but faces opposition from Republicans who control the House. A narrower approach, the Veterans Medical Marijuana Safe Harbor Act, would protect veterans using cannabis pursuant to Veterans Affairs recommendations from federal employment discrimination. The bill has bipartisan support but has not advanced beyond committee consideration